TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer
This study has been completed.
Information provided by:
First received: January 21, 2003
Last updated: July 21, 2011
Last verified: June 2011
This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer|
Resource links provided by NLM:
Further study details as provided by Telik:
Contacts and Locations